Full-Time

Director – Corporate Counsel

Transactions

Confirmed live in the last 24 hours

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops biopharmaceuticals for serious diseases

Compensation Overview

$202k - $336.6k/yr

Senior, Expert

Tarrytown, NY, USA

Relocation benefits may be offered.

Category
Legal
Legal & Compliance
Requirements
  • JD with excellent law school credentials
  • Licensed to practice law in New York or eligible for licensure as a registered in-house counsel preferred
  • At least 7 years of legal experience at a law firm and/or in-house, with some biotech/pharmaceutical and/or health care experience preferred
  • Solid understanding of contracts and related law
  • Experience with contracts involving data privacy and intellectual property
  • High level of business acumen
  • Excellent contract drafting and negotiation proficiency
  • Exceptional oral and written communication skills
  • Interpersonal and conflict resolution capability
Responsibilities
  • Providing legal support for a particular area of business transactions, which may include research collaboration agreements, master services agreements, consulting services agreements, license agreements, data use agreements, laboratory services agreements and confidentiality agreements, among others
  • Maintaining subject matter expertise in data privacy laws and the Regeneron privacy policies and advising Transaction Law colleagues and clients on developments of importance
  • Providing ongoing one-on-one support to members of the Transaction Law team and coordinating with internal teams and external resources to negotiate and finalize data privacy language in third-party agreements
  • Responding to U.S. and ex-U.S. contracting questions
  • Managing updates to group’s data privacy contracting playbook
  • Creating data privacy contracting tools and training materials
  • Managing office hours with internal business partners
  • Developing and training on privacy contracting tools and requirements
  • Acting as liaison for the Transactions Law Group with the Data Privacy Office on data privacy policy questions and approaches
Desired Qualifications
  • Ability to work independently while meeting aggressive deadlines and juggling multiple matters
  • Ability to maintain an objective perspective while developing and maintaining strong partnerships with key stakeholder/client organizations and protecting Regeneron’s interests
  • Ability to work effectively and professionally with colleagues and clients at all levels of the organization and in a collaborative, team-oriented environment
  • Ability to effectively convey to, and respond to questions from, colleagues and key stakeholders, on data privacy law concepts
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops medicines aimed at treating serious diseases such as cancer, eye diseases, and allergic conditions. The company uses its own technologies and extensive research to create new therapies, often working with academic institutions and other pharmaceutical companies to enhance its efforts. Regeneron stands out from competitors by focusing on strategic partnerships that allow for shared development costs and profits. Its goal is to improve patient outcomes through effective treatments while ensuring compliance with safety standards.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Greenburgh, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of 23andMe assets boosts Regeneron's consumer genomics and drug discovery.
  • Collaboration with Sanofi and Viz.ai enhances AI solutions for COPD management.
  • AIM4 trial launch with Sanofi reflects commitment to precision medicine.

What critics are saying

  • 23andMe acquisition may face regulatory scrutiny, delaying strategic benefits.
  • AERIFY-2 study failure could impact investor confidence in COPD projects.
  • 23andMe acquisition raises privacy concerns, affecting consumer trust.

What makes Regeneron Pharmaceuticals unique

  • Regeneron excels in leveraging proprietary technologies for drug discovery and development.
  • The company has strong collaborations with academic and research institutions.
  • Regeneron's strategic partnerships enhance its R&D capabilities and market reach.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Company News

PharmiWeb
Jun 2nd, 2025
Itepekimab Met The Primary Endpoint In One Of Two Copd Phase 3 Studies

Itepekimab met the primary endpoint in one of two COPD phase 3 studies. AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefit. AERIFY-2 study, a second Phase 3 study, did not meet the primary endpoint despite a benefit seen earlier in the study

MarketBeat
Jun 1st, 2025
Summit Global Investments Invests $849,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Regeneron Pharmaceuticals Inc. purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter worth approximately $1,045,822,000.

CNBC
May 27th, 2025
23Andme To Delist From Nasdaq, Deregister With Sec

A sign is posted in front of the 23andMe headquarters in Sunnyvale, California, on Feb. 1, 2024.Justin Sullivan | Getty Images23andMe on Tuesday announced it will voluntarily delist from the Nasdaq and de-register with the U.S. Securities and Exchange Commission, according to a release. The move comes after Regeneron Pharmaceuticals said earlier this month that it will acquire "substantially all" of 23andMe's assets for $256 million. The drugmaker came out on top following a bankruptcy auction for 23andMe, a once high-flying genetic testing company that filed for for Chapter 11 bankruptcy protection in March.This is breaking news. Please refresh for updates

Pharmaceutical Technology
May 20th, 2025
ATS 2025: Sanofi and Regeneron to launch new AIM4 trial for personalised asthma care

At the American Thoracic Society (ATS) 2025 Congress on 19 May, Sanofi and Regeneron announced the launch of a new Phase IIIb/IV clinical trial, AIM4, during an evening industry symposium.

Regeneron Pharmaceuticals
May 20th, 2025
Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness | Regeneron Pharmaceuticals Inc.

Purchase is subject to bankruptcy court and regulatory approvals Regeneron will prioritize the privacy, security and ethical use of 23andMe’s customer data; stands ready to work with independent, court-appointed Customer Privacy Ombudsman Planned purchase to strengthen Regeneron’s ongoing